Emergence Therapeutics
European biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Emergence Therapeutics is a biotechnology company focused on developing Antibody-Drug Conjugates (ADCs) for the treatment of hard-to-treat cancers. The company's lead program, ETx 22, targets Nectin 4 and aims to deliver higher efficacy with lower risk of off-target side effects and the ability to avoid tumor resistance. ETx 22 utilizes an innovative linker and payload technology to achieve these goals. Emergence Therapeutics serves patients with difficult-to-treat cancers and operates in the biopharmaceutical market. The business model revolves around the development and commercialization of first or best-in-class ADCs, driven by therapeutic need. Revenue is generated through the development and potential future sales of these ADCs, as well as possible partnerships and licensing agreements.
Keywords: ADCs, Nectin 4, cancer treatment, biotechnology, biopharmaceutical, tumor resistance, innovative technology, therapeutic need, commercialization, partnerships.